Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma
Erasca announced that the FDA granted Fast Track Designation to ERAS-0015 for the treatment of metastatic pancreatic adenocarcinoma, facilitating development and expedited review. Updated Phase 1 data from the AURORAS-1 trial demonstrated a 57% unconfirmed overall response rate in second-line or later KRAS G12X pancreatic cancer patients at the recommended dose of 32 mg.
Key figures
- Drug Name
- ERAS-0015
- Phase Of Trial
- Phase 1
- Dose
- 32 mg once daily
- Uorr 8w
- 57%
- Indication
- 2L+ KRAS G12X pancreatic ductal adenocarcinoma
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.